OAM
VKTX icon

Oxford Asset Management’s Viking Therapeutics VKTX Stock Holding History

Oxford Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$633K Buy
16,221
+8,030
+98% +$259K 0.31% 83
2026
Q1 		$267K Buy
+8,191
New +$263K 0.11% 288
2025
Q1 		– Sell
-7,428
Closed -$299K – 722
2024
Q4 		$299K Buy
+7,428
New +$424K 0.13% 259

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Oxford Asset Management's VKTX Position: Q2 2026 in Review

Oxford Asset Management increased its Viking Therapeutics (VKTX) stake by 98% in Q2 2026, buying an estimated $259K and bringing the position to 16,221 shares worth $633K. The position accounts for 0.31% of the portfolio, ranked #83.

Oxford Asset Management first reported a position in VKTX in Q4 2024 and has held it in 3 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Oxford Asset Management held 16,221 shares of Viking Therapeutics worth $633K as of Q2 2026.
  • Oxford Asset Management bought 8,030 Viking Therapeutics shares in Q2 2026, an estimated $259K.
  • Viking Therapeutics made up 0.31% of Oxford Asset Management's portfolio in Q2 2026, its #83 holding.
  • Oxford Asset Management first reported a position in Viking Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.